Cancer Immunology and Immunotherapy, 1432-0851

Journal

More filtering options
  1. 2020
  2. 2019
  3. Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics

    Anna Felberg, Aleksandra Urban, Anna Borowska, Grzegorz Stasiłojć, Michał Taszner, Andrzej Hellmann, Anna Maria Blom & Marcin Okrój, 2019, In : Cancer Immunology, Immunotherapy. 68, 4, p. 587-598

    Research output: Contribution to journalArticle

  4. 2018
  5. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression

    Jonathan P.O. Hebb, Adriane R. Mosley, Felipe Vences-Catalán, Narendiran Rajasekaran, Anna Rosén, Peter Ellmark & Dean W. Felsher, 2018 Jan, In : Cancer Immunology, Immunotherapy. 67, 1, p. 47-60

    Research output: Contribution to journalArticle

  6. 2017
  7. Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation

    Peter Ellmark, Sara M. Mangsbo, Christina Furebring, Per Norlén & Thomas H. Tötterman, 2017 Jan, In : Cancer Immunology and Immunotherapy. 66, 1, p. 1-7 7 p.

    Research output: Contribution to journalArticle

  8. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis

    Viktoria Bergqvist, Erik Hertervig, Peter Gedeon, Marija Kopljar, Håkan Griph, Sara Kinhult, Ana Carneiro & Jan Marsal, 2017, In : Cancer Immunology and Immunotherapy. 66, 5, p. 581-592

    Research output: Contribution to journalArticle

  9. 2015
  10. Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence.

    Marcin Okroj, Emelie Holmquist, Elise Nilsson, Lola Anagnostaki, Karin Jirström & Anna Blom, 2015, In : Cancer Immunology and Immunotherapy. 64, 4, p. 467-478

    Research output: Contribution to journalArticle

  11. 2013
  12. Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion.

    Sara Fritzell, Emma Sandén, Sofia Eberstål, Edward Visse, Anna Darabi & Peter Siesjö, 2013, In : Cancer Immunology and Immunotherapy. 62, 9, p. 1463-1474

    Research output: Contribution to journalArticle

  13. Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications

    Fredrik B. Thoren, Harald Anderson & Orjan Strannegard, 2013, In : Cancer Immunology and Immunotherapy. 62, 10, p. 1547-1551

    Research output: Contribution to journalArticle

  14. 2012
  15. Inhibition of cyclooxygenase-2 enhances immunotherapy against experimental brain tumors.

    Sofia Eberstål, Wiaam Badn, Sara Fritzell, Magnus Esbjörnsson, Anna Darabi, Edward Visse & Peter Siesjö, 2012, In : Cancer immunology, immunotherapy : CII. 61, 8, p. 1191-1199

    Research output: Contribution to journalArticle

  16. 2011
  17. Changes in immunocompetent cells after interstitial laser thermotherapy of breast cancer.

    Kristin Huld-Haraldsdottir, Kjell Ivarsson, Karin Jansner, Unne Stenram & Karl-Göran Tranberg, 2011, In : Cancer immunology, immunotherapy : CII. 60, p. 847-856

    Research output: Contribution to journalArticle

  18. 2009
  19. Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack.

    Marcin Okroj, Leticia Corrales, Anna Stokowska, Ruben Pio & Anna Blom, 2009, In : Cancer immunology, immunotherapy : CII. 58, p. 1773-1782

    Research output: Contribution to journalArticle

  20. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy

    Robbert G. van der Most, Andrew J. Currie, Sathish Mahendran, Amy Prosser, Anna Darabi, Bruce W. S. Robinson, Anna K. Nowak & Richard A. Lake, 2009, In : Cancer Immunology and Immunotherapy. 58, 8, p. 1219-1228

    Research output: Contribution to journalArticle

  21. 2000
  22. 1997
  23. Prevention of superantigen-induced tolerance in vivo by interleukin-2 treatment. 1996 Submitted

    Hans Belfrage, M Dohlsten, G Hedlund & T Kalland, 1997, In : Cancer Immunology and Immunotherapy. 44, 2, p. 77-82

    Research output: Contribution to journalArticle

  24. 1995
  25. Enhanced and prolonged efficacy of superantigen-induced cytotoxic T lymphocyte activity by interleukin-2 in vivo

    Hans Belfrage, M Dohlsten, G Hedlund & T Kalland, 1995, In : Cancer Immunology and Immunotherapy. 41, 2, p. 87-94

    Research output: Contribution to journalArticle

  26. 1994
  27. Combined activation of murine lymphocytes with staphylococcal enterotoxin and interleukin-2 results in additive cytotoxic activity

    Hans Belfrage, Pallonji Bhiladvala, G Hedlund, M Dohlsten & T Kalland, 1994, In : Cancer Immunology and Immunotherapy. 38, 4, p. 265-71

    Research output: Contribution to journalArticle